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Abstract
Background: Collapse of the femoral head associated with nontraumatic osteonecrosis (NOFH) is one of the most
common causes of disability in young adult patients. Excessive bone resorption by osteoclast coincident with the
suppression of osteogenesis are believed to be responsible for collapse progression. Alendronate that inhibits bone
resorption by inducing osteoclast apoptosis has been traditionally used for treating NOFH; however, several reports
documented serious complications by the use of this drug. On the other hand, teriparatide activates osteoblasts
leading to an overall increase in bone volume, and is expected to reduce the progression of femoral head collapse
in NOFH. Therefore, the present study was undertaken to examine pharmacological effects of teriparatide on
collapse progression of NOFH and to compare these effects with alendronate.
Methods: We conducted a retrospective study in our facility for comparing the pharmacological effects of teriparatide
and alendronate on 32 NOFH patients diagnosed with osteoporosis. Between 2007 and 2013, patients were treated
with daily administration of 20 μg teriparatide (15 patients: 18 hips), or with 35 mg of alendronate once a week (17
patients: 22 hips). The mean period of follow-up was 18.7 months. The progression of collapse was evaluated prior to
the administration and later every three months by anteroposterior radiographs. Collapse progression with > 1 mm
was defined as advanced collapse, while with < 1 mm was defined as stable radiologic disease. Student’s t-test and the
chi-square test was used to do compare the pharmacological effects of the two groups.
Results: Treatment with terparatide had a tendency to reduce the rate of advanced collapse as compared to that with
alendronate (p = 0.105). Kaplan-Meier curves related to stable radiologic disease showed that teriparatide-treated patients
had better stable states than these treated with alendronate (p = 0.08, log-rank test). Moreover, treatment with teriparatide
resulted in a significant reduction in collapse progression as compared to that with alendronate, noted at the end of
follow-up period (p = 0.049).
Conclusion: The present study suggests that teriparatide has greater pharmacological effects than alendronate for
treating NOFH and preventing the collapse of femoral head.
Trial registration: The registration number in UMIN Clinical Trial Registry is UMIN000017582. The date of registration is
May 5, 2015.
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Background
Complete collapse of the femoral head is one of the
major complication of nontraumatic osteonecrosis
(NOFH), resulting in dysfunction of the hip and disabil-
ity in patients. Collapse of the femoral head occurs in
75% of NOFH cases within three years and in 80% of
patients within four years of onset of hip pain [1, 2].
The disease is typically progressive and mainly occurs
in young population, whereas and most of patients
eventually require total hip replacement (THR) within
three years [3–5]. In fact, 10% of THRs performed in
the United States is due to NOFH [4]. The pathogen-
esis of NOFH remains unclear, but involves interrup-
tion of the blood supply to the femoral head leading
to osteonecrosis [5]. Consequently, osteonecrosis in-
duces osteoclastic and osteoblastic remodeling pro-
cesses that cause collapse of the femoral head of the
necrotic region [6–8].
Efficient pharmacological treatment that prevents bone
collapse is not currently available, and therefore, identi-
fying novel drug with potential benefits is extremely
desirable. Coordinating osteoclastic and osteoblastic ac-
tivities is an attractive approach and may offer good
therapeutic option for NOFH. Bisphosphonates that
inhibit excessive osteoclast-mediated bone resorption
have proven to reduce the incidence of collapse of
femoral head in osteonecrotic hip [9–11]. Nonetheless,
Chen et al reported that alendronate has only minor ef-
fects on the disease progression and has failed to prevent
THR in majority of patients [12]. On the other hand, ter-
iparatide is a recombinant form of parathyroid hormone
that has been used as anabolic agent for treatment of
osteoporosis. Teriparatide has positive effects on osteo-
blast differentiation and activation leading to bone ne-
crosis lesions repair [13–15]. In support of this concept,
Jiang et al reported that teriparatide improves trabecular
morphology and increases cancellous bone volume and
cortical bone thickness [16, 17]. Teriparatide enhances
the bone healing in osteonecrotic jaw, and reduces
steroid-induced osteonecrosis of femoral head [18–21].
Although several clinical studies highlight the advanta-
geous effects of terpiaratide for the treatment of osteo-
necrosis, the clinical benefit of teriparatide for NOFH
has not been systematically studied. Therefore, the
present study was undertaken to determine whether teri-
paratide could offer greater pharmacological effects than
alendronate, which is known to be the traditional
pharmacological option for preventing collapse progres-
sion of the femoral head.
Methods
Patients
Between Jan 1, 2007, and Dec 31, 2013, fifty-three
patients who were diagnosed with NOFH had undergone
treatment for osteoporosis; nineteen patients had re-
ceived teriparatide, and thirty-four patients had received
alendronate. Twenty-one patients (four patients on teri-
paratide treatment and seventeen patients on alendro-
nate treatment) were excluded from this study; fifteen
patients had been followed for less than 6 months. Four
patients developed osteoarthritis of the hip. In two pa-
tients, the administration periods were not identified.
We conducted retrospective study for these thirty-two
patients. Fifteen patients (18 hips; three patients were
observed in bilateral hips) received teriparatide, and
seventeen patients (22 hips; five patients were observed
in bilateral hips) received alendronate. The patients’
mean age was 38.7 years, with 4 male and 11 female
patients, in the teriparatide group, and 46.8 years, with 9
male and 8 female patients, in the alendronate group
(Table 1). The mean follow-up was 18.7 months. The
radiologic stages of the patients were stages 1, 2, and 3A
in the Japanese Investigation Committee (JIC) staging
system, and the locations of osteonecrosis were type C-1
and C-2 in the JIC classification system [22]. Stage 1 is
the phase that osteonecrosis can be detected by
magnetic resonance imaging (MRI) or bone scintigram,
cannot be detected by X-ray. In stage 2, demarcating
sclerosis is seen without collapse of femoral head on
X-ray images. Stage 3 shows collapse of the femoral head
without joint-space narrowing, and is subdivided into
stage 3A (less than 3 mm of collapse) and 3B (3 mm or
more of collapse). Type C lesion occupies more than the
medial two-thirds of the weight-bearing portion. Type
C-2 lesion extends laterally to the acetabular edge,
whereas type C-1 lesion does not [22].









Mean age, years (range) 38.7 (22-59) 46.8 (19-67) 0.053
Mean body weight (kg) 59.2 59.2 0.499
Mean body mass index (kg/m2) 22.9 21.5 0.127
Mean follow up, days (range) 523.7 (217-719) 606.9 (336-724) 0.071
Radiologic stage in JIC
1 3 (16.7%) 0 (0%)
2 8 (44.4%) 17 (77.3%)
3A 7 (38.9%) 5 (22.7%)
Locations of osteonecrosis in JIC
Type C-1 8 (44.4%) 8 (36.4%)
Type C-2 10 (55.6%) 14 (63.6%)
JIC Japanese Investigation Committee
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Treatments
Teriparatide (20 μg) was subcutaneously administered
once per day [23, 24] while alendronate (35 mg) was
orally administered once per week [25]. In Japan, daily
20 μg teriparatide and weekly 35 mg alendronate admin-
istration is approved for the treatment of osteoporosis.
None of the patients received vitamin D3, and non-ste-
roid anti-inflammatory agents were given when needed
to relief the pain.
Assessment of collapse progression
Plain anteroposterior hip radiographs were taken prior
to the treatment courses and at every interval of
between three to six-month follow-up visit. The JIC
staging and locations of osteonecrosis were estimated on
X-ray examinations or MRI. Collapse progression of the
femoral head was evaluated on anteroposterior hip
radiographs in neutral rotation before administration
and at every follow-up (Fig. 1) with the same imaging
conditions, for avoidance of differences caused by magnifi-
cation effects. Collapse progression with > 1 mm was de-
fined as “advanced collapse”, and as “stable radiologic
disease” when collapse progression was < 1 mm. The
follow-up periods for the treatment courses were assigned
for two years.
Statistical analysis
Student’s t-test and the chi-square test was used to com-
pare the pharmacological effects of the two groups. Nor-
mality of the samples were confirmed by Shapiro-Wilk
test. Stable radiologic disease analysis was performed
using Kaplan-Meier analysis. Inter-group comparison of
Kaplan-Meier data was performed using the log-rank
test. A p-value < 0.05 was deemed significant, as de-
scribed in the figure legends. Analyses were performed
using Ekuseru-Toukei 2010 (Social Survey Research
Information Co., Ltd., Tokyo, Japan).
Results
To investigate the pharmacological usefulness of teri-
paratide for treatment of NOFH, a 6-months to 2-years
follow-up study of 15 patients (18hips) who received
teriparatide was performed. In parallel, same follow-up
study of 17 patients (22 hips) who received alendronate
was performed to compare the efficiencies of teripara-
tide. There were no complications observed on the
patients during the period of study caused by the treat-
ment course of teriparatide or alendronate. Notably,
collapse progression was observed in 59.1% of patients
received alendronate treatment, and in 33.3% of patients
received teriparatide treatment, suggesting that teripara-
tide had a tendency to reduce collapse progression of
femoral head (Table 2). Next, Kaplan-Meier curves were
generated for patients with advanced collapse as the
end-point (Fig. 2). Although there was no significant
difference between the two treatments, patients treated
by teriparatide exhibited a 6-month-prolonged radiologic
disease (94.4% (90% CI 85.6 -100)) as compared to
alendronate (77.3% (90% CI 62.6 – 92.0)). Moreover, a
longer 1-year stability (83.3% (90% CI 68.9 – 97.8)) was
noted in patients treated by teriparatide than that noted in
patients treated by alendronate (53.6% (90% CI 35.8 – 71.3)
(p = 0.08, log-rank test). Moreover, treatment with teripara-
tide resulted in a significant reduction in collapse progres-
sion (0.67 mm) as compared to that with alendronate
(1.24 mm; p = 0.049) (Table 2). Representative case 1 is a
Fig. 1 The progression of collapse of the femoral head of NOFH. The progression of collapse (D1-D2) before administration (left) and at every follow-up
(right) using anteroposterior radiographs. The baseline is the top of the greater trochanter of the femur
Table 2 The occurrence rate of advanced collapse in the teriparatide
and alendronate groups at the end of follow-up and the final collapse
progression in the teriparatide and alendronate groups
Teriparatide group Alendronate group p value
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67-year-old man with NOFH, type C-2 in the JIC classifica-
tion and JIC stage 2 that was treated by alendronate (Fig. 3).
Collapse progression was 3.3 mm after 21 months of treat-
ment course, and eventually THR was performed (Fig. 3).
Representative case 2 is a 27-year-old woman with NOFH,
type C-2 in the JIC classification and JIC stage 1 that was
treated by teriparatide (Fig. 4). Collapse progression of the
femoral head did not occur over a period of 20 months
(Fig. 4). Taken together, our data suggest that teriparatide is
promising therapeutic agent for NOFH.
Discussion
NOFH causes decreased vascular supply to the trabecu-
lar bone of the femoral head, resulting in collapse of
articular surface of the femoral head and severe hip pain
in young adults. The precise mechanism of collapse in
NOFH has not been clarified; however, excessive bone
resorption by osteoclast in necrotic regions is thought to
induce collapse of the femoral head [7]. The disease is
progressive and once collapse of the femoral head oc-
curs, osteoarthritis of the hip joint is developed in few
years. Most of cases need THR for relieving the severe
hip pain caused by osteoarthritis; however, due to
limited durability of THR, this procedure is not recom-
mended for young adults. Therefore, conservative treat-
ment that prevents collapse progression of the femoral
head in early stage of NOFH is highly demanded.
Several pharmacological agents have been used for
treatment of NOFH, including statins [26], anticoagu-
lants [27, 28], prostacyclin [29, 30], and bisphosphonates.
Bisphosphonates, namely alendronate, are the most
common used [31]. Alendronate prevents early collapse
of the femoral head in NOFH [32], and improves clinical
function with better rate of collapse [11]. However, the
frequently reported failures of alendronate in preventing
collapse progression and its serious complications in-
cluding osteonecrosis and atypical fractures [12, 33–38]
highlight the need for more effective and safer thera-
peutic option for the treatment of NOFH.
We speculate that enhancing osteogenesis might
contribute to the prevention of femoral head collapse
progression. Teriparatide is known to increase the
Fig. 2 The Kaplan-Meier curves of the teriparatide group (solid line) and the alendronate group (dotted line) with advanced collapse as the end-point
Fig. 3 Case 1. Sixty-seven years old man with NOFH. a Anteroposterior radiograph and magnetic resonance imaging (T1WI) at the first examination
showing NOFH. After diagnosis, alendronate was administered. b Collapse of the femoral head has progressed. c Eventually, THR was performed
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life-span of mature osteoblasts by preventing their
apoptosis [39]. Teriparatide has been reported to in-
crease cancellous bone volume and connectivity, and
to improve trabecular morphology with a shift toward
more plate-like structure [18]. Moreover, intermittent
use of teriparatide exerts anabolic action on cortical
bone with improved cancellous bone microarchitec-
tures [40]. Recently, several case reports showed suc-
cessful outcome of teriparatide for the treatment of
osteonecrosis [18–20] and fracture-healing [41]. Con-
sistently, our study showed that treatment with teri-
paratide resulted in lower rate of collapse progression
than alendronate. Treatment with alendronate has
been reported to be correlated with high incidence of
collapse progression (65.6%) [12]. Likewise, in our
study, the rate of head collapse in the alendronate-
treated group fell within this range (59.1%), while
lesser incidence was noted in teriparatide-treated pa-
tients (33.3%). This can be explained by the fact that
teriparatide enhances osteoblast activity in the nec-
rotic lesion, leading to an increase in cancellous bone
volume and trabecular thickness of the femoral head.
This study has some limitations that must be pointed
out. The mean follow-up period was longer in the alen-
dronate group, and the patient’s average age of teripara-
tide group was 8 years younger than alendronate group.
This may give an advantage of bone growth. The current
study is retrospective study, covers small sample size
(number of patients), doesn't include the clinical out-
come or functional parameters post treatments, and
doesn't consider the differences between radiological
stage or location of osteonecrosis in the patients. Further
study, including a larger number of samples with longer
follow-up period is needed to conclusively demonstrate
the therapeutic use of teriparatide for treatment of
NOFH.
Conclusion
This is the first study demonstrating that teriparatide is
a potent conservative option for treatment of NOFH.
The treatment course by teriparatide results in lesser
collapse progression of the femoral head than that by
alendronate, which is considered as the traditional
pharmacological option for preventing collapse progres-
sion of the femoral head.
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Fig. 4 Case 2. Twenty-seven years old woman with NOFH. a Anteroposterior radiograph and magnetic resonance imaging (T1WI) at the first examination
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Arai et al. BMC Musculoskeletal Disorders  (2017) 18:24 Page 5 of 6
Received: 6 July 2016 Accepted: 22 December 2016
References
1. Merle D'Aubigné R, Postel M, Mazabraud A, Massias P, Gueguen J, France P.
Idiopathic necrosis of the femoral head in adults. J Bone Joint Surg Br.
1965;47:612–33.
2. Ohzono K, Saito M, Sugano N, Takaoka K, Ono K. The fate of nontraumatic
avascular necrosis of the femoral head. A radiologic classification to
formulate prognosis. Clin Orthop Relat Res. 1992;277:73–8.
3. Aaron RK, Lennox D, Bunce GE, Ebert T. The conservative treatment of
osteonecrosis of the femoral head. A comparison of core decompression
and pulsing electromagnetic fields. Clin Orthop Relat Res. 1989;249:209–18.
4. Mont MA, Jones LC, Sotereanos DG, Amstutz HC, Hungerford DS.
Understanding and treating osteonecrosis of the femoral head. Instr Course
Lect. 2000;49:169–85.
5. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral
head. J Bone Joint Surg Am. 1995;77:459–74.
6. Kenzora JE, Steele RE, Yosipovitch ZH, Glimcher MJ. Experimental
osteonecrosis of the femoral head in adult rabbits. Clin Orthop Relat Res.
1978;130:8–46.
7. Wang C, Wang X, Xu XL, Yuan XL, Gou WL, Wang AY, Guo QY, Peng J, Lu SB.
Bone microstructure and regional distribution of osteoblast and osteoclast
activity in the osteonecrotic femoral head. PLoS One. 2014;9:e96361.
8. Shibayama K. Idiopathic osteonecrosis of the femoral head in the elderly.
Kurume Med J. 2000;47:37–43.
9. Agarwala S, Sule A, Pai BU, Joshi VR. Study of alendronate in avascular
necrosis of bone. J Assoc Physicians India. 2001;49:949–50.
10. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate
prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat
Res. 2006;443:273–9.
11. Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of
avascular necrosis of the femoral head: follow-up to eight years. J Bone
Joint Surg Br. 2009;91:1013–8.
12. Chen CH, Chang JK, Lai KA, Hou SM, Chang CH, Wang GJ. Alendronate in
the prevention of collapse of the femoral head in nontraumatic
osteonecrosis: a two-year multicenter, prospective, randomized, double-
blind, placebo-controlled study. Arthritis Rheum. 2012;64:1572–8.
13. Niall HD, Sauer RT, Jacobs JW, Keutmann HT, Segre GV, O'Riordan JL,
Aurbach GD, Potts Jr JT. The amino-acid sequence of the amino-
terminal 37 residues of human parathyroid hormone. Proc Natl Acad
Sci U S A. 1974;71:384–8.
14. Dobnig H, Turner RT. The effects of programmed administration of human
parathyroid hormone fragment (1-34) on bone histomorphometry and
serum chemistry in rats. Endocrinology. 1997;138:4607–12.
15. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone
mass and connectivity in ovariectomized rats can be restored by combined
treatment with parathyroid hormone and estradiol. J Clin Invest. 1993;91:2479–87.
16. Mosekilde L, Søgaard CH, Danielsen CC, Tørring O. The anabolic effects of
human parathyroid hormone (hPTH) on rat vertebral body mass are also
reflected in the quality of bone, assessed by biomechanical testing: a
comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology.
1991;129:421–8.
17. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant
human parathyroid hormone (1-34) [teriparatide] improves both cortical
and cancellous bone structure. J Bone Miner Res. 2003;18:1932–41.
18. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis
of the mandible: possible application for intermittent low-dose parathyroid
hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007;65:573–80.
19. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide
[recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009;36:1835–7.
20. Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment
of advanced bisphosphonate-related osteonecrosis of the mandible with
adjunctive teriparatide therapy. Head Neck. 2011;33:1366–71.
21. Dong Y, Li Y, Huang C, Gao K, Weng X. Systemic application of teriparatide
for steroid induced osteonecrosis in a rat model. BMC Musculoskelet Disord.
2015;16:163.
22. Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001
revised criteria for diagnosis, classification, and staging of idiopathic
osteonecrosis of the femoral head. J Orthop Sci. 2002;7:601–5.
23. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T.
Effects of teriparatide on bone mineral density and bone turnover markers in
Japanese subjects with osteoporosis at high risk of fracture in a 24-month
clinical study: 12-month, randomized, placebo-controlled, double-blind and
12-month open-label phases. Bone. 2010;47:493–502.
24. Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H. Effects of
teriparatide in Japanese and non-Japanese populations: bridging findings
on pharmacokinetics and efficacy. J Bone Miner Metab. 2012;30:326–37.
25. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, et al.
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily
in Japanese patients with osteoporosis: a double-blind, randomized study.
J Bone Miner Metab. 2005;23(5):382–8.
26. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients
receiving steroids. Clin Orthop Relat Res. 2001;386:173–8.
27. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of
stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005;435:164–70.
28. Wang Y, Yin L, Li Y, Liu P, Cui Q. Preventive effects of puerarin on alcohol-
induced osteonecrosis. Clin Orthop Relat Res. 2008;466:1059–67.
29. Disch AC, Matziolis G, Perka C. The management of necrosis-associated and
idiopathic bone-marrow oedema of the proximal femur by intravenous
iloprost. J Bone Joint Surg Br. 2005;87:560–4.
30. Jäger M, Tillmann FP, Thornhill TS, Mahmoudi M, Blondin D, Hetzel GR, et al.
Rationale for prostaglandin I2 in bone marrow oedema—from theory to
application. Arthritis Res Ther. 2008;10:R120.
31. Green J, Clézardin P. The molecular basis of bisphosphonate activity: a
preclinical perspective. Semin Oncol. 2010;37:S3–11.
32. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate
to prevent early collapse of the femoral head in patients with nontraumatic
osteonecrosis. A randomized clinical study. J Bone Joint Surg Am.
2005;87:2155–9.
33. Wong PK, Borromeo GL, Wark JD. Bisphosphonate-related osteonecrosis of
the jaw in non-malignant bone disease. Rheumatol Int. 2013;33:2189–98.
34. Conte Neto N, Spolidorio LC, Andrade CR, Bastos A S, Guimarães M,
Marcantonio Jr E. Experimental development of bisphosphonate-related
osteonecrosis of the jaws in rodents. Int J Exp Pathol. 2013;94:65–73.
35. Bocanegra-Pérez MS, Vicente-Barrero M, Sosa-Henríquez M, Rodríguez-
Bocanegra E, Limiñana-Cañal JM, López-Márquez A, et al. Bone metabolism
and clinical study of 44 patients with bisphosphonate-related osteonecrosis
of the jaws. Med Oral Patol Oral Cir Bucal. 2012;17:e948–55.
36. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral
fracture during and after bisphosphonate use. N Engl J Med. 2014;371:974–6.
37. Meling T, Nawab A, Harboe K, Fosse L. Atypical femoral fractures in
elderly women: a fracture registry-based cohort study. Bone Joint J.
2014;96-B(8):1035–40.
38. Blum L, Cummings K, Goulet JA, Perdue AM, Mauffrey C, Hake ME. Atypical
femur fractures in patients receiving bisphosphonate therapy: etiology and
management. Eur J Orthop Surg Traumatol. 2016;26:371–7.
39. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by
prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest.
1999;104:439–46.
40. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al.
Effects of daily treatment with parathyroid hormone on bone
microarchitecture and turnover in patients with osteoporosis: a paired
biopsy study. J Bone Miner Res. 2001;16:1846–53.
41. Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA.
Stimulation of fracture-healing with systemic intermittent parathyroid
hormone treatment. J Bone Joint Surg Am. 2008;90:120–7.
Arai et al. BMC Musculoskeletal Disorders  (2017) 18:24 Page 6 of 6
